{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:56Z","timestamp":1788281216395,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-03646-3","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T23:22:14Z","timestamp":1749079334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical factors associated with delayed ischemic and non-ischemic adverse events in clazosentan therapy after aneurysmal subarachnoid hemorrhage: early insights from a multicenter prospective registry"],"prefix":"10.1007","volume":"48","author":[{"given":"Taku","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Hokari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruto","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinari","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Gekka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayasu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"3646_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.hest.2023.10.003","volume":"5","author":"Y Akamatsu","year":"2024","unstructured":"Akamatsu Y, Chida K, Miyoshi K, Kojima D, Nomura JI, Setta K, Chiba T, Koji T, Fujiwara S, Kashimura H, Kubo Y, Ogasawara K (2024) Fluid balance management with loop diuretics in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A case series. Brain Hemorrhages 5:74\u201378. https:\/\/doi.org\/10.1016\/j.hest.2023.10.003","journal-title":"Brain Hemorrhages"},{"key":"3646_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1161\/STROKEAHA.121.035699","volume":"53","author":"M Dayyani","year":"2022","unstructured":"Dayyani M, Sadeghirad B, Grotta JC, Zabihyan S, Ahmadvand S, Wang Y, Guyatt GH, Amin-Hanjani S (2022) Prophylactic therapies for morbidity and mortality after aneurysmal subarachnoid hemorrhage: A systematic review and network Meta-Analysis of randomized trials. Stroke 53:1993\u20132005. https:\/\/doi.org\/10.1161\/STROKEAHA.121.035699","journal-title":"Stroke"},{"key":"3646_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10143-006-0045-5","volume":"30","author":"JG De Oliveira","year":"2007","unstructured":"De Oliveira JG, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V (2007) Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. Neurosurg Rev 30:22\u201331","journal-title":"Neurosurg Rev"},{"key":"3646_CR4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.2.jns212914","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O, Tominaga T (2022) Effects of Clazosentan on cerebral vasospasm\u2013related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg 137:1707\u20131717. https:\/\/doi.org\/10.3171\/2022.2.jns212914","journal-title":"J Neurosurg"},{"key":"3646_CR5","first-page":"359","volume":"61","author":"N Fujimoto","year":"2024","unstructured":"Fujimoto N, Takeyama K, Aikawa Y, Suzuki R, Ichida H, Nishimoto S, Du M, Togo O, Abe N, Yoshimura S (2024) Safety and efficacy of Clazosentan sodium (PIVLAZ \u00ae intravenous solution 150\u00a0mg) in postoperative patients with subarachnoid hemorrhage due to cerebral aneurysm: interim analysis of the Post-Marketing survey in Japan. Shinryo Shinyaku Med Cons New-Remed 61:359\u2013377","journal-title":"Shinryo Shinyaku Med Cons New-Remed"},{"key":"3646_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","volume":"44","author":"M Fujimura","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T (2017) Preventive effect of Clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis 44:59\u201367. https:\/\/doi.org\/10.1159\/000475824","journal-title":"Cerebrovasc Dis"},{"key":"3646_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3171\/2018.9.JNS181975","volume":"132","author":"A Giede-Jeppe","year":"2020","unstructured":"Giede-Jeppe A, Reichl J, Spr\u00fcgel MI, L\u00fccking H, Hoelter P, Ey\u00fcpoglu IY, Kuramatsu JB, Huttner HB, Gerner ST (2020) Neutrophil-to-lymphocyte ratio as an independent predictor for unfavorable functional outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg 132:400\u2013407. https:\/\/doi.org\/10.3171\/2018.9.JNS181975","journal-title":"J Neurosurg"},{"key":"3646_CR8","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/j.wneu.2019.04.222","volume":"128","author":"RT Higashida","year":"2019","unstructured":"Higashida RT, Bruder N, Gupta R, Guzman R, Hmissi A, Marr A, Mayer SA, Roux S, Weidauer S, Aldrich EF (2019) Reversal of vasospasm with Clazosentan after aneurysmal subarachnoid hemorrhage: A pilot study. World Neurosurg 128:e639\u2013e648. https:\/\/doi.org\/10.1016\/j.wneu.2019.04.222","journal-title":"World Neurosurg"},{"key":"3646_CR9","doi-asserted-by":"publisher","first-page":"E314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, Hsiang-Yi Chou S, Cruz-Flores S, Dangayach NS, Derdeyn CP, Du R, H\u00e4nggi D, Hetts SW, Ifejika NL, Johnson R, Keigher KM, Leslie-Mazwi TM, Lucke-Wold B, Rabinstein AA, Robicsek SA, Stapleton CJ, Suarez JI, Tjoumakaris SI, Welch BG (2023) 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage: A guideline from the American heart association\/american stroke association. Stroke 54:E314\u2013E370. https:\/\/doi.org\/10.1161\/STR.0000000000000436","journal-title":"Stroke"},{"key":"3646_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.hest.2023.12.001","volume":"5","author":"T Itazu","year":"2024","unstructured":"Itazu T, Ikedo T, Tsutsui T, Niwa A, Kushi Y, Ozaki S, Yamada N, Shimonaga K, Hamano E, Yamada K, Imamura H, Mori H, Iihara K, Kataoka H (2024) Impact of strict fluid management on the treatment outcome of Clazosentan for cerebral vasospasm. Brain Hemorrhages 5:69\u201373. https:\/\/doi.org\/10.1016\/j.hest.2023.12.001","journal-title":"Brain Hemorrhages"},{"key":"3646_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2176\/jns-nmc","volume":"65","author":"S Kajiwara","year":"2024","unstructured":"Kajiwara S, Kawano T, Hasegawa Y, Nakamura Y, Sakata K, Kikuchi J, Hirohata M, Morioka M (2024) Impact of Clazosentan on vasospasm reduction and functional recovery after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 65:29\u201336. https:\/\/doi.org\/10.2176\/jns-nmc","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3646_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hest.2024.01.004","volume":"5","author":"T Kimura","year":"2024","unstructured":"Kimura T, Suzuki K, Sato H, Shibata A, Take Y, Ooigawa H, Yoshimura M, Kohyama S, Kurita H (2024) Initial results of Clazosentan with multiple-drug management for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Brain Hemorrhages 5:79\u201384. https:\/\/doi.org\/10.1016\/j.hest.2024.01.004","journal-title":"Brain Hemorrhages"},{"key":"3646_CR13","unstructured":"KURODA S (2023) Japanese stroke society guideline 2021 for the treatment of stroke [Revised version 2023]. Kyowa-Kikaku"},{"key":"3646_CR14","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/j.wneu.2019.06.040","volume":"130","author":"PMR Lai","year":"2019","unstructured":"Lai PMR, Gormley WB, Patel N, Frerichs KU, Aziz-Sultan MA, Du R (2019) Age-Dependent radiographic vasospasm and delayed cerebral ischemia in women after aneurysmal subarachnoid hemorrhage. World Neurosurg 130:e230\u2013e235. https:\/\/doi.org\/10.1016\/j.wneu.2019.06.040","journal-title":"World Neurosurg"},{"key":"3646_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12028-021-01291-4","volume":"36","author":"A Lai","year":"2022","unstructured":"Lai A, Tan CO, Vranic J, Weidauer S, Leslie-Mazwi T, Hirsch JA, Gupta R (2022) Clazosentan for improvement of time to peak perfusion in patients with angiographically confirmed severe vasospasm. Neurocrit Care 36:240\u2013247. https:\/\/doi.org\/10.1007\/s12028-021-01291-4","journal-title":"Neurocrit Care"},{"key":"3646_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-022-01708-0","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A (2022) Clazosentan: first approval. Drugs 82:697\u2013702. https:\/\/doi.org\/10.1007\/s40265-022-01708-0","journal-title":"Drugs"},{"key":"3646_CR17","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL MacDonald","year":"2008","unstructured":"MacDonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A (2008) Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 39:3015\u20133021. https:\/\/doi.org\/10.1161\/STROKEAHA.108.519942","journal-title":"Stroke"},{"key":"3646_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N (2011) Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618\u2013625. https:\/\/doi.org\/10.1016\/S1474-4422(11)70108-9","journal-title":"Lancet Neurol"},{"key":"3646_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL MacDonald","year":"2012","unstructured":"MacDonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Nowbakht P, Roux S, Kassell N (2012) Randomized trial of Clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 43:1463\u20131469. https:\/\/doi.org\/10.1161\/STROKEAHA.111.648980","journal-title":"Stroke"},{"key":"3646_CR20","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.wnsx.2023.100253","volume":"21","author":"T Maeda","year":"2023","unstructured":"Maeda T, Okawara M, Osakabe M, Yamaguchi H, Maeda T, Kurita H (2023) Initial real-world experience of Clazosentan for subarachnoid hemorrhage in Japan. World Neurosurg X 21:100253. https:\/\/doi.org\/10.1016\/j.wnsx.2023.100253","journal-title":"World Neurosurg X"},{"key":"3646_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.hest.2023.11.006","volume":"5","author":"H Maeda","year":"2024","unstructured":"Maeda H, Izumo T, Okamura K, Yamaguchi S, Morofuji Y, Matsuo T (2024) Evolving approaches in the management of patients with subarachnoid hemorrhage from 2002 to 2022: the impact of Clazosentan and treatment modalities on outcomes. Brain Hemorrhages 5:55\u201361. https:\/\/doi.org\/10.1016\/j.hest.2023.11.006","journal-title":"Brain Hemorrhages"},{"key":"3646_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3171\/2024.4.jns232191","volume":"142","author":"SA Mayer","year":"2024","unstructured":"Mayer SA, Bruder N, Citerio G, Defreyne L, Dubois C, Gupta R, Higashida R, Marr A, Nguyen TN, Roux S, Smr\u010dka M, Torn\u00e9 RT, Aldrich EF (2024) REACT: a randomized trial to assess the efficacy and safety of Clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 142:98\u2013109. https:\/\/doi.org\/10.3171\/2024.4.jns232191","journal-title":"J Neurosurg"},{"key":"3646_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/17474930221090347","volume":"17","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, Iguchi Y, Shiokawa Y, Takagi Y, Ohtsuki T, Kinouchi H, Okada Y, Takahashi JC, Nakase H, Kakuda W (2022) Japan stroke society guideline 2021 for the treatment of stroke. Int J Stroke 17:1039\u20131049. https:\/\/doi.org\/10.1177\/17474930221090347","journal-title":"Int J Stroke"},{"key":"3646_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10143-024-02345-9","volume":"47","author":"T Mochizuki","year":"2024","unstructured":"Mochizuki T, Ryu B, Shima S, Kamijyo E, Ito K, Ando T, Kushi K, Sato S, Inoue T, Kawashima A, Kawamata T, Okada Y, Niimi Y (2024) Comparison of efficacy between Clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan. Neurosurg Rev 47:113. https:\/\/doi.org\/10.1007\/s10143-024-02345-9","journal-title":"Neurosurg Rev"},{"key":"3646_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10143-023-02104-2","volume":"46","author":"S Muraoka","year":"2023","unstructured":"Muraoka S, Asai T, Fukui T, Ota S, Shimato S, Koketsu N, Nishizawa T, Araki Y, Saito R (2023) Real-world data of Clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. Neurosurg Rev 46:195. https:\/\/doi.org\/10.1007\/s10143-023-02104-2","journal-title":"Neurosurg Rev"},{"key":"3646_CR26","doi-asserted-by":"publisher","first-page":"e943303","DOI":"10.12659\/MSM.943303","volume":"30","author":"T Mutoh","year":"2024","unstructured":"Mutoh T, Aono H, Seto W, Kimoto T, Tochinai R, Moroi J, Ishikawa T (2024) Factors influencing discontinuation of Clazosentan therapy in elderly patients with aneurysmal subarachnoid hemorrhage: A retrospective study from a Japanese single center. Med Sci Monit 30:e943303. https:\/\/doi.org\/10.12659\/MSM.943303","journal-title":"Med Sci Monit"},{"key":"3646_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.hest.2023.11.007","volume":"5","author":"R Nishii","year":"2024","unstructured":"Nishii R, Ohta T, Fukui N, Koyanagi M, Goto M, Takeda J, Fukumitsu R, Sunohara T, Takano Y, Teranishi K, Nakajima K, Naramoto Y, Yamamoto Y, Kawade S, Sakisuka R, Takamatsu T, Tokuda M, Tomita H, Yoshimoto M, Sakai N (2024) A high cardiothoracic ratio increases the risk of severe pulmonary complications after early initiation of Clazosentan in patients with aneurysmal subarachnoid hemorrhage. Brain Hemorrhages 5:85\u201390. https:\/\/doi.org\/10.1016\/j.hest.2023.11.007","journal-title":"Brain Hemorrhages"},{"key":"3646_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1227\/neu.0000000000002601","volume":"93","author":"JPM Pontes","year":"2023","unstructured":"Pontes JPM, Santos MDC, Gibram FC, Rodrigues NMV, Cavalcante-Neto JF, Barros ADM, Solla DJF (2023) Efficacy and safety of Clazosentan after aneurysmal subarachnoid hemorrhage: an updated Meta-Analysis. Neurosurgery 93:1208\u20131219. https:\/\/doi.org\/10.1227\/neu.0000000000002601","journal-title":"Neurosurgery"},{"key":"3646_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10143-024-03173-7","volume":"48","author":"S Raja","year":"2025","unstructured":"Raja S, Raja A, Shuja MH, Ali A (2025) Clazosentan\u2019s dual edge in managing vasospasm following aneurysmal subarachnoid hemorrhage: an updated systematic review, meta-analysis, and meta-regression of clinical outcomes and safety profiles. Neurosurg Rev 48:20","journal-title":"Neurosurg Rev"},{"key":"3646_CR30","doi-asserted-by":"publisher","first-page":"1413632","DOI":"10.3389\/fneur.2024.1413632","volume":"15","author":"H Sakata","year":"2024","unstructured":"Sakata H, Kanoke A, Uchida H, Haryu S, Omodaka S, Kimura N, Yoshida M, Niizuma K, Tominaga T, Endo H (2024) Prophylactic management of cerebral vasospasm with Clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol 15:1413632. https:\/\/doi.org\/10.3389\/fneur.2024.1413632","journal-title":"Front Neurol"},{"key":"3646_CR31","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/j.wneu.2018.11.143","volume":"123","author":"J Song","year":"2019","unstructured":"Song J, Xue YQ, Wang YJ, Xu P, Sun DK, Chen W (2019) An update on the efficacy and safety profile of Clazosentan in cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A Meta-Analysis. World Neurosurg 123:e235\u2013e244. https:\/\/doi.org\/10.1016\/j.wneu.2018.11.143","journal-title":"World Neurosurg"},{"key":"3646_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.hest.2023.10.006","volume":"5","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Nakajima H, Ichikawa T, Yasuda R, Okada T, Goto F, Ito S, Horiuchi Y, Kitano Y, Nishikawa H, Fujimoto M, Toma N (2024) Beneficial effects of Clazosentan add-on treatment on delayed cerebral microcirculatory disturbances after aneurysmal subarachnoid hemorrhage. Brain Hemorrhages 5:62\u201368. https:\/\/doi.org\/10.1016\/j.hest.2023.10.006","journal-title":"Brain Hemorrhages"},{"key":"3646_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","volume":"79","author":"K Toyoda","year":"2022","unstructured":"Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, Kamiyama K, Yazawa Y, Kawada S, Sasaki M, Terasaki T, Miwa K, Koge J, Ishigami A, Wada S, Iwanaga Y, Miyamoto Y, Minematsu K, Kobayashi S (2022) Twenty-Year change in severity and outcome of ischemic and hemorrhagic strokes. JAMA Neurol 79:61\u201369. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4346","journal-title":"JAMA Neurol"},{"key":"3646_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9\u201317. https:\/\/doi.org\/10.3171\/jns.2005.103.1.0009","journal-title":"J Neurosurg"},{"key":"3646_CR35","doi-asserted-by":"publisher","first-page":"105861","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105861","volume":"30","author":"S Yun","year":"2021","unstructured":"Yun S, Yi HJ, Lee DH, Sung JH (2021) Systemic inflammation response index and systemic Immune-inflammation index for predicting the prognosis of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 30:105861. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2021.105861","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-03646-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:20:30Z","timestamp":1772079630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-03646-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3646"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-03646-3","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the central Institutional Review Board (IRB) of Hokkaido University Hospital (No. 022\u20130137) and the IRBs of each participating institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}